Targeted drug combo for first-line DLBCL in older adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zanubrutinib) as a first treatment for older adults (70+) with a common type of lymphoma called DLBCL. The goal is to see if this approach is effective and well-tolerated without standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have diffuse large B-cell lymphoma (DLBCL) that is CD20-positive (a common type).
- You have not had any previous treatment for your lymphoma.
- You have at least one tumor that can be measured on a scan.
- Your liver, kidney, and blood counts are in an acceptable range (your doctor can check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.